💊
Antineoplastic Agents
8 articles analyzed — Average score : 49/100
Grade distribution
Authors' conclusions
Articles
B
Mostly reliable (58/100)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Positive
Reck M et al.·The New England Journal of Medicine·Jan 2016
B
Mostly reliable (57/100)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. Positive
Motzer RJ et al.·The New England Journal of Medicine·Sep 2015
B
Mostly reliable (57/100)
Pembrolizumab versus Ipilimumab in Advanced Melanoma. Positive
Robert C et al.·The New England Journal of Medicine·Apr 2015
C
Nuanced (52/100)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. Positive
Le DT et al.·The New England Journal of Medicine·Jun 2015
C
Nuanced (48/100)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. Positive
Robson M et al.·The New England Journal of Medicine·Aug 2017
C
Nuanced (47/100)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Positive
Chapman PB et al.·The New England journal of medicine·Jun 2011
D
Unreliable (44/100)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Positive
Piccart-Gebhart MJ et al.·The New England journal of medicine·Oct 2005
D
Unreliable (27/100)
Determination of carboplatin in plasma and tumor by high-performance liquid chromatography-mass spectrometry. Inconclusive
Guo P. et al.·Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·Jan 2003